期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Role of Soluble Factors in Immune and Normal Sera in the Control of Giardiasis Due to Giardia Iamblia
1
作者 R.K.SRIVASTAVA N.SETHI +1 位作者 N.GUPTA A.K.AGARWAL 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 1992年第2期87-91,共5页
Hyperimmune sera (HIS), raised against crude giardia antigen, on in vitro interaction, caused more agglutination of Giardia lamblia trophozoites. Heat inactivated HIS possessed a comparable agglutinating activity as t... Hyperimmune sera (HIS), raised against crude giardia antigen, on in vitro interaction, caused more agglutination of Giardia lamblia trophozoites. Heat inactivated HIS possessed a comparable agglutinating activity as the non-inactivated controls. Non-inactivated normal (unimmunized) serum caused immobilization of Giardia trophozoite, which was checked on heat inactivation. Antibodies in immune sera are mainly responsible for agglutination, whereas the heat labile non-immune components control the mobility of the intestinal parasite. 展开更多
关键词 Role of Soluble Factors in Immune and normal Sera in the Control of Giardiasis Due to Giardia Iamblia
暂未订购
Immune checkpoint blockade for cancer therapy: current progress and perspectives 被引量:2
2
作者 Hongying YE Weijie LIAO +2 位作者 Jiongli PAN Yin SHI Qingqing WANG 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 2025年第3期203-226,共24页
Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade(ICB), which can potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor i... Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade(ICB), which can potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified;some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration(FDA) for clinical treatment. However, limited responses and immune-related adverse events(ir AEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy. 展开更多
关键词 Immune checkpoint blockade Cancer immunotherapy Tumor immune evasion Immune normalization
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部